Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors increased its Omeros stake by 85.2% in the first quarter, adding 82,646 shares to hold 179,594 shares worth approximately $1.9 million. Institutional investors and hedge funds collectively own 48.79% of Omeros.
• Omeros reported quarterly earnings of $0.02 per share, beating the $0.27-per-share loss analysts expected, while revenue of $28.53 million exceeded the $12.69 million consensus estimate.
• OMER shares opened at $17.35, near their 12-month high of $18.14. Analysts maintain a “Moderate Buy” consensus with a $38 average price target, although some firms recently downgraded the stock to “Hold”; a company director also sold 7,500 shares under a pre-arranged trading plan.

Dimensional Fund Advisors LP raised its holdings in shares of Omeros Corporation (NASDAQ:OMER - Free Report) by 85.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,594 shares of the biopharmaceutical company's stock after acquiring an additional 82,646 shares during the period. Dimensional Fund Advisors LP owned approximately 0.25% of Omeros worth $1,897,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in shares of Omeros during the fourth quarter valued at about $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros in the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros in the 4th quarter valued at about $33,000. Assetmark Inc. acquired a new position in Omeros during the 1st quarter valued at about $38,000. Finally, Tower Research Capital LLC TRC increased its stake in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 11,971 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Price Performance

Shares of OMER opened at $17.35 on Friday. The firm's 50 day moving average is $10.74 and its 200-day moving average is $11.50. The stock has a market capitalization of $1.26 billion, a P/E ratio of 13.55 and a beta of 2.54. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $18.14.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. As a group, equities research analysts forecast that Omeros Corporation will post -0.94 EPS for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the completion of the sale, the director owned 35,067 shares in the company, valued at approximately $407,127.87. This represents a 17.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on OMER shares. Wall Street Zen lowered shares of Omeros from a "buy" rating to a "hold" rating in a research note on Sunday, June 7th. Weiss Ratings upgraded shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. HC Wainwright reiterated a "buy" rating on shares of Omeros in a research note on Monday, July 27th. Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $38.00.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q2 earnings and revenue beat estimates: Omeros reported earnings of $0.02 per share, compared with analysts’ expected loss of $0.27, while revenue reached $28.53 million versus the $12.69 million consensus estimate. Results also improved from a $0.53-per-share loss a year earlier. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: YARTEMLEA and balance-sheet initiatives supported sentiment: The earnings update highlighted strong YARTEMLEA sales momentum, debt reduction and planned share buybacks, strengthening the investment case by improving commercial growth prospects and financial flexibility. OMER Stock Soars After YARTEMLEA Sales Momentum
• Positive Sentiment: Analyst maintained a bullish outlook: H.C. Wainwright reiterated its Buy rating and $33 price target, citing strong YARTEMLEA launch performance and reduced C5 competition. The target implies considerable upside relative to recent trading levels. Omeros Buy Rating and $33 Price Target
• Positive Sentiment: Options activity signaled increased trading interest: Traders bought 12,612 call options, 235% above the average daily volume. Although options activity does not guarantee future gains, the surge indicates heightened bullish speculation and investor attention.
• Neutral Sentiment: Board expanded: Omeros appointed veteran investor Joseph Schocken and increased its board from eight to nine members. The appointment could add investment and governance expertise, though its direct financial impact is not yet clear. Omeros Appoints Joseph Schocken to Board

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source